Raltegravir Production Cost Reports

The report provides a detailed analysis essential for establishing a raltegravir production plant. It encompasses all critical aspects necessary for raltegravir production, including the cost of raltegravir production, raltegravir plant cost, raltegravir production costs, and the overall raltegravir production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a raltegravir production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Raltegravir is an antiretroviral medication that is classified as an HIV integrase strand transfer inhibitor (INSTI). It is used to treat HIV-1 infection in adults, adolescents, and children by blocking the HIV integrase enzyme. It prevents viral DNA from integrating into the host cell's genome and halts replication. It is FDA-approved for treatment-experienced patients with multidrug-resistant HIV strains. Its application also includes treatment of naïve individuals, where it shows rapid viral load reduction when combined with other antiretrovirals in regimens. It is available in oral tablet and suspension forms. Its common side effects include nausea and headache, but it is generally well-tolerated in pediatric and adult populations.

The market for raltegravir is driven by its growing application in the HIV antiretroviral sector. The growing global HIV cases and demand for integrase inhibitors against resistant strains boost its demand. The generic entries improve affordability, awareness initiatives, and expanded access in emerging markets, that supports its market.

The industrial raltegravir procurement is influenced by diagnoses, government screening programs, and combination therapy innovations. The long-acting formulations, green API production, along with HIV drug resistance, regulatory barriers, and competition from advanced INSTIs impacts its market dynamics.

Raw Material for Raltegravir Production

According to the raltegravir production plant project report, the key raw materials used in the production of raltegravir include 5-methyl-1,3,4-oxadiazole-2-carboxylic acid, 2-amino-2-methylpropanenitrile, dialkyl acetylenedicarboxylate, and 4-fluorobenzyl halide.

Production Process of Raltegravir

The extensive raltegravir production cost report consists of the following major industrial production process:

1. By convergent synthetic route: Raltegravir is manufactured through a convergent synthetic route involving the preparation of two key fragments. The 5-methyl-1,3,4-oxadiazole-2-carbonyl chloride is derived from 5-methyl-1,3,4-oxadiazole-2-carboxylic acid via chlorination with oxalyl chloride or thionyl chloride, and the pyrimidinone core. It is assembled from 2-amino-2-methylpropanenitrile reacted with a dialkyl acetylenedicarboxylate like DMAD to form an amidoxime adduct. This goes through thermal rearrangement and cyclisation to yield the dimethylamino-substituted pyrimidinone. The 4-fluorobenzyl group is then introduced via N-alkylation of this pyrimidinone using 4-fluorobenzyl halide, followed by oxidation or functionalisation to install the 5-hydroxy substituent. The hydroxy-pyrimidinone is acylated with the oxadiazole carbonyl chloride under basic conditions to form the amide-linked intermediate. Finally, selective N-methylation of the pyrimidinone nitrogen follows using a chemoselective agent to raltegravir as free base.

Raltegravir has the molecular formula of C20H21FN6O5 with a molecular weight of 444.42 g/mol. It is a white to off-white powder that is available as the potassium salt. It is classified as BCS Class II with poor aqueous solubility but higher solubility in acidic and basic media. It has a melting point around 230–235 degree Celsius (decomposition). It has a logP value of 1.6–2.5, making it moderately lipophilic. It has pKa values of 2.1 (carboxamide), 7.5 (oxadiazole), and 11.4 (pyrimidinone). It has a polar surface area of around 150 Ų, and its stability is affected by acidic and basic conditions, leading to hydrolysis.